A woman's heart

Michael S. Ewer,Stefan Glück

DOI: https://doi.org/10.1002/cncr.24219

IF: 6.9209

2009-05-01

Cancer

Abstract:Adjuvant therapy in postmenopausal women with breast cancer may contribute to the expression of underlying cardiovascular disease or expose the heart to additional toxicities. Tamoxifen remains an important component of endocrine therapy for breast cancer, although major clinical trials of the aromatase inhibitors (AIs) anastrozole, letrozole, and exemestane suggest that these agents are more effective and better tolerated alternatives to tamoxifen. The AIs inhibit the conversion of androgens to estrogen in postmenopausal women; consequently, their mechanism of action differs from that of tamoxifen. Accordingly, although it has been observed that tamoxifen has some favorable effects on cardiovascular risk, such as reducing total cholesterol levels, because of its partial estrogen-agonist properties, no such effects exist for the AIs. Some studies, particularly those that compare the AIs with tamoxifen, have suggested a less favorable impact of adjuvant AI therapy on cardiovascular risk. Comorbid conditions, including cardiovascular disease, emerge as competing causes of death as women with breast cancer continue to live longer, and the potential impact of adjuvant therapies on cardiovascular risk becomes an increasingly important consideration for clinicians. Cancer 2009. (c) 2009 American Cancer Society.

oncology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the impact of adjuvant endocrine therapy (especially aromatase inhibitor AI and tamoxifen) on cardiovascular health in post - menopausal women with breast cancer. Specifically, the research focuses on:

1. **Cardiovascular side effects of adjuvant endocrine therapy**: With the improvement of breast cancer treatment effects and the prolongation of patient survival, cardiovascular diseases have become one of the main causes of death in these patients. Therefore, it is particularly important to understand the specific impacts of different endocrine treatment drugs (such as aromatase inhibitors and tamoxifen) on cardiovascular risks.

2. **Comparison between aromatase inhibitors and tamoxifen**: The paper makes a detailed comparison between the third - generation aromatase inhibitors (such as anastrozole, letrozole and exemestane) and the traditional drug tamoxifen in terms of their effects on reducing breast cancer recurrence rates and mortality, and explores the potential impacts of these drugs on cardiovascular health.

3. **Changes in cardiovascular risks**: The research also explores the situation of increased cardiovascular disease risks in post - menopausal women due to endocrine changes (such as the decline in estrogen levels), and how adjuvant endocrine therapy further affects this risk.

4. **Analysis of clinical trial data**: The paper analyzes the data of multiple large - scale clinical trials, such as ATAC, BIG 1 - 98, IES, etc., to evaluate the differences in the incidence of cardiovascular events between aromatase inhibitors and tamoxifen.

Through these analyses, the paper aims to provide guidance for clinicians on how to balance the breast cancer treatment effects and cardiovascular risks, especially when choosing adjuvant endocrine treatment regimens.